Introducing Andrew Saarni, Director, Fermentation Process Development & Scale-Up

In today’s blog, we are pleased to introduce Andrew Saarni, Head of Fermentation Process Development & Scale-Up at Antheia.
Future of Pharma Insights: Q&A with Antheia and TAPI
As global pharma leaders convene in New York City for DCAT Week 2026, Antheia is proud to highlight its strategic partnership with TAPI – Technology and API Services.
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships
Savile to drive portfolio expansion and strategic alliances as Antheia expands commercialization of critical pharmaceutical ingredients MENLO PARK, Calif., March 19, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced the appointment of Dr. Chris Savile as Vice President, Business Development and Partnerships. Savile will drive strategic partnerships to expand Antheia’s […]
Introducing Chris Savile, Vice President, Business Development and Partnerships

We sat down with Chris to learn more about his career journey, what inspired him to join Antheia’s mission, and what he’ll focus on in this new role.
ASPR to invest in domestic production of ingredient for pain management, overdose reversal medications

The Administration for Strategic Preparedness and Response announced March 5 that it will invest in the domestic production of thebaine, an ingredient used to manufacture medications for pain management, alcohol use disorder and the reversal of opioid overdose.
Antheia expands US biosynthesis project to strengthen drug supply chains

The expanded BioMaP consortium agreement supports commercial-scale domestic production of two critical pharmaceutical ingredients using biosynthesis.
Christina Smolke, Antheia CEO: A Fortt Knox Conversation

Christina Smolke, CEO of Antheia, announces a $9 million expansion of its U.S. government partnership with ASPR to onshore critical medicine manufacturing.
Antheia Secures Additional Funding from HHS to Onshore Supply Chains

Antheia, a biosynthesis company delivering pharmaceutical manufacturing and innovation, has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million.
Antheia Secures Additional $9 Million in Expanded BioMaP-Consortium Project Agreement to Onshore Pharmaceutical Supply Chains
U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines MENLO PARK, Calif., March 4, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 […]
Antheia seals 2nd series C funding close, hitting more than $175M in a year

Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul.